Page 1

Press Release 19. November 2021 Third quarter report Q3-2021 - focusing on next trial ( 0205 ) Cessatech A / S ( " Cessatech " or the " Company " ) today releases its results for the period 1 July - 30 September 2021. The third quarter report is available as an attached document to this press release and on www.cessatech.com under Investor , ' Filings & Reports ' . The company is on track with planned activities , has initiated recruitment of trial 0206 - a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures , and getting ready for trial 0205 . Third quarter 2021 ( 1 July - 30 September ) : Net revenue was KDKK 0 Operating result was KDKK -3.484 Net result was KDKK -2.876 Cash at bank end of the period was KDKK 5.935 Earnings per share * was KDKK -0,78 ● ● • Solidity ** was 87 % cessa tech rethinking child treatments * Earnings per share ( DKK per share ) : Operating result divided by the average number of shares during the period . The total number of shares as of 30 September 2021 amounted to 3.680.000 shares , the average number of shares during the third quarter was 3.680.000 . There have been no increases in the number of shares since the completion of the IPO in December 2020 . ** Solidity : Total equity divided by total capital and liability . Highlights during third quarter 2021 Ongoing analysis of trial 0204 , final results expected end of the year Initiated ( first patient enrolled ) and ongoing recruitment for trial 0206 ● Submitted protocol for authorities approval for trial 0205 ● Cessatech announced the issuance of its first US patent covering CT001 ( 2 Nov 2021 ) Finalisation of GMP clinical manufacturing batch production of CT001 for trial 0205 Continue to build the organization to lead the development of CT001 " The third quarter of 2021 has focused much on getting trial 0205 ready for recruitment - trial 0205 is a randomised , double - blind study comparing the analgesic effect of CT001 for treatment of acute pain in adults undergoing surgical removal of an impacted mandibular third molar . We hope to receive regulatory approval from authorities by the end 2021 so we can initiate recruitment . The outlook is really encouraging for the Company especially also with the first US patent issuance for CT001 " says Jes Trygved , CEO Cessatech A / S - Kanonbådsvej 2 , DK - 1437 Copenhagen - info@cessatech.com - Cvr 4129 3055